Why does an mRNA-based vaccine hold promise? What have pre-clinical trials shown?
In December last year, Russia announced that it had developed a new, mRNA-based personalised ‘vaccine’ for cancer which would be available free for patients by early 2025. Media reports state that Andrey Kaprin, General Director of the Radiology Medical Research Center of the Russian Ministry of Health, spoke to Radio Rossiya about the vaccine. Reports also say that Alexander Gintsburg, Director of the Gamaleya National Research Center for Epidemiology and Microbiology, said the vaccine’s pre-clinical trials had shown that it suppresses tumour development and potential metastases.